Tesamorelin: adverse events and evidence limits
The six-month subcutaneous tesamorelin trial in antiretroviral-treated HIV patients with abdominal fat accumulation reported injection-site bruising, paresthesias and serious events in both groups. [1]
This short summary does not estimate event frequencies. [1]
What the studies reported
| Effect | Model or participants | How often or as described | Source |
|---|---|---|---|
| Injection-site bruising | Antiretroviral-treated HIV patients with abdominal fat accumulation, subcutaneous tesamorelin, six months | Reported; this short summary does not estimate event frequencies | [1] |
| Paresthesias | The same patients | Reported; no frequency given | [1] |
| Serious events | The same patients | Reported in both groups; no frequency given | [1] |
References
- Takara L Stanley et al. (2014). Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation. 10.1001/jama.2014.8334.